Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to understand and provide written informed consent.~* Age 19-60, inclusive.~* Diagnosis documented according to DSM-IV of OCD.~* Exhibits moderate to severe OCD symptoms and a minimum score of 16 or greater -YBOCS at screening.~* Willing and able to discontinue current medications taken for the treatment of OCD.~* Able to attend and participate in all study visits.~* Agree to continue if in current psychosocial therapy throughout the remainder of the study.~* If female and of child-bearing potential, willing to use an acceptable method of birth control for the duration of the study.~* If male, willing to use barrier method of birth control or had previous vasectomy.~Exclusion Criteria:~* Have other DSM-IV Axis I diagnoses.~* Pregnant as confirmed by urine analysis, or lactating, or unwilling to comply with use of contraception.~* Unwilling or unable to washout (discontinue) from prohibited medications such as antidepressants (See Appendix 2).~* Depression symptoms with a score of 15 or greater on the MADRS at screening.~* Current suicidal ideation or plan within the last 30 days.~* Have a medical condition which, in the opinion of the investigator, makes study participation unsafe or noncompliant.~* Abnormal physical exam or laboratory values which, in the opinion of the investigator, makes study participation unsafe or may require introduction of concomitant medications during the course of the study.~* Benzodiazepine and/or similar sedative-hypnotic or anxiolytic use or abuse within 15 days of potential flumazenil treatment: patients must not be habituated to benzodiazepines and must provide a urine sample that is negative for benzodiazepines, must not be taking supra-therapeutic doses of zolpidem (AmbienTM) or zaleplon (SonataTM ). (See Appendix 2).~* Patients who are taking Phenobarbital for a documented seizure disorder can be admitted. Patients with a seizure disorder being managed with clonazepam (KlonopinTM ) or other benzodiazepine cannot participate, patients must not be taking TCA, lithium, methylxanthines, isoniazid, propoxyphene, monoamine oxidase inhibitors, bupropion HCL, and cyclosporine. (See Appendix 2).~* Previously treated with flumazenil for OCD.~* AIDS as determined by self-report.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Sugar Pill, Placebo (Type: PLACEBO_COMPARATOR): None
- Flumazenil (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).